523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center

Documenti analoghi

• 523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center
  di: Jianjun Gao, et al.
  Pubblicazione: (2023-11-01)
• Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
  di: Jennifer Wang, et al.
  Pubblicazione: (2021-07-01)
• Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma
  di: Jianjun Gao, et al.
  Pubblicazione: (2026-03-01)
• Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
  di: Mohammad Jad Moussa, et al.
  Pubblicazione: (2024-06-01)
• Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
  di: Pavlos Msaouel, et al.
  Pubblicazione: (2025-01-01)